Healthcare Finance News January 14, 2025
Jeff Lagasse

Overall, these top 25 drugs were responsible for nearly $50 billion in total Medicare Part D spending in 2022, AARP finds.

The brand-name drugs covered under Medicare Part D have nearly doubled in price, and 25 of them are now up 98% since they debuted in the market, a new AARP Public Policy Institute analysis has found.

These lifetime price increases often greatly exceeded the corresponding rate of general inflation, AARP found.

The analysis also found that, on average, more than 40% of the current list prices for the top 25 drugs is due to price increases that have occurred since the products first entered the market.

All of the data was based on the 25 brand-name drugs with the...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Insurance, Medicare, Pharma, Pharma / Biotech, Survey / Study, Trends
Drug Price Negotiation Requires Oversight To Protect Older Americans
Prices of 25 Medicare Part D drugs up 98%
Podcast: The Scope of Medicare Fraud
Study reveals cost differences between Medicare Advantage and traditional Medicare patients in cancer drugs
Harnessing AI to reduce Medicare errors, improve accuracy, and ease physician burnout

Share This Article